Dyadic International Inc. (DYAI) - 2024 Annual Report Summary
Business Context and Reporting Period
Company: Dyadic International, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Dyadic is a biotechnology platform company developing microbial protein production technologies. Its core assets include the C1 platform (focused on pharmaceutical applications like vaccines and monoclonal antibodies) and the Dapibus™ platform (focused on non-pharmaceutical alternative proteins for food, nutrition, and industrial markets). The company operates primarily in the U.S. with a satellite office in the Netherlands and relies heavily on third-party Contract Research Organizations (CROs) for R&D.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3,495,389 | $2,898,806 |
| Net Loss | $(5,809,159) | $(6,795,461) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.24) |
| Cash and Cash Equivalents | $6,506,750 | $6,515,028 |
| Short-Term Investments | $2,756,577 | $748,290 |
| Total Liquidity (Cash + Investments) | $9,263,327 | $7,263,318 |
| Convertible Notes Outstanding (Principal) | $5,090,000 | $0 |
| Accumulated Deficit | $(86,086,480) | $(80,277,321) |
Revenue Composition: License revenue increased significantly to $1.89 million (driven by Proliant and Inzymes agreements), while R&D revenue decreased to $1.61 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by approximately 20.6% year-over-year, primarily due to a $1.54 million increase in license revenue from new agreements with Proliant Health and Biologicals and Inzymes ApS.
- Reduced Net Loss: Net loss improved by $986,000 (14.5% decrease) compared to 2023. This was driven by higher license revenue and a $1.25 million reduction in R&D expenses following the completion of the Phase 1 clinical trial for the DYAI-100 vaccine candidate.
- Debt Financing: In March 2024, the company issued $6.0 million in 8.0% Senior Secured Convertible Promissory Notes. As of year-end, $910,000 of these notes had been converted into common stock, leaving approximately $5.09 million in principal outstanding.
- Investment Portfolio: Short-term investment securities increased from $0.75 million in 2023 to $2.76 million in 2024, reflecting the deployment of proceeds from the convertible note offering.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Commercialization: The company anticipates commercializing certain alternative protein products in 2025 via the Dapibus™ platform.
- Grants: In November 2024, Dyadic secured a $3.09 million grant from the Bill & Melinda Gates Foundation for cell line development targeting RSV and malaria. In March 2025 (subsequent event), the company received a funding award from CEPI for vaccine development.
- Liquidity: Management believes existing cash, investments, and the Gates Foundation grant are sufficient to fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Going Concern: The company has a history of net losses and an accumulated deficit of $86.1 million. Continued profitability depends on securing additional funding, licensing deals, or government grants.
- Customer Concentration: Two significant customers accounted for 54.8% of 2024 revenue. Loss of these customers could materially impact operations.
- Third-Party Dependence: The company relies heavily on CROs for R&D; two CROs accounted for 93% of research services purchased in 2024.
- Regulatory Uncertainty: No products are currently approved for sale. Success depends on regulatory approval for C1-produced pharmaceuticals and market acceptance of Dapibus™ alternative proteins.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the covenants of the $6.0 million Convertible Notes (due 2027), including restrictions on additional indebtedness and dividends.
- Grant Utilization: Monitor the disbursement and utilization of the $3.09 million Gates Foundation grant and the subsequent CEPI award to ensure they cover projected R&D costs.
- Customer Retention: Assess the renewal status of contracts with the two customers representing 54.8% of revenue.
- Commercialization Timeline: Track progress on the 2025 commercialization targets for Dapibus™ products (e.g., recombinant serum albumin with Proliant).
- Cash Burn Rate: Review quarterly cash flow statements to ensure the $9.3 million liquidity position remains sufficient given the ongoing operating losses.